Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause ...Middle East

PR Newswire - News
Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause
Study evaluated 24-week efficacy and safety of Astellas' fezolinetant in women considered unsuitable for hormone therapy TOKYO, June 27, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the...

Hence then, the article about phase 3b trial of fezolinetant shows positive topline results for treatment of vms due to menopause was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News